Barry D. Quart - 05 Jun 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
05 Jun 2024
Transactions value $
$0
Form type
4
Filing time
07 Jun 2024, 16:35:08 UTC
Previous filing
03 Jul 2023
Next filing
05 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +4.37K +87.46% 9.37K 06 Jun 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Award $0 +19K $0.00 19K 05 Jun 2024 Class A Common Shares 19K $19.71 Direct F2
transaction KNSA Restricted Share Units Award $0 +3.17K $0.00 3.17K 05 Jun 2024 Class A Common Shares 3.17K Direct F1, F3
transaction KNSA Restricted Share Units Options Exercise $0 -4.37K -100% $0.00* 0 06 Jun 2024 Class A Common Shares 4.37K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 5, 2024.
F3 The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024.
F4 The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs.